Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Case report 3

Murray K. Dalinka, R. E. Brennan, Arthur S. Patchefsky · Skeletal Radiology · 1976 · 4.1K citations

Amplification of <i>MET</i> may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Gromoslaw A. Smolen, Raffaella Sordella, Beth Muir et al. · Proceedings of the National Academy of Sciences · 2006 · 484 citations · Full text

Medicine, Cancer Biology, Oncology +17

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Sai‐Hong Ignatius Ou, Eunice L. Kwak, Christina T. Siwak-Tapp et al. · Journal of Thoracic Oncology · 2011 · 439 citations

Medicine, Oncology, Pharmacology +17

<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

Jochen K. Lennerz, Eunice L. Kwak, A. B. Ackerman et al. · Journal of Clinical Oncology · 2011 · 430 citations · Full text

Medicine, Molecular Biology, Oncology +17